Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 31c
August 2, 2017 4:21 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.03, $0.31 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $42.06 million versus the consensus estimate of $40.31 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
... More